Ascendis Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Revenue	1,047	720.13	363.64	266.72	51.17	7.78
Revenue Growth	113.35%	98.03%	36.34%	421.20%	557.93%	11.87%
Cost of Revenue	91.13	94.92	44.26	44.4	12.14	3.52
Gross Profit	955.9	625.22	319.38	222.32	39.04	4.26
Selling, General & Admin	571.28	457.87	291.14	264.41	221.23	160.18
Research & Development	284.02	303.62	307	413.45	379.62	295.87
Operating Expenses	697.23	761.49	598.15	677.86	600.85	456.05
Operating Income	258.66	-136.27	-278.76	-455.54	-561.81	-451.79
Interest Expense	-128.4	-80.65	-65.5	-44.07	-30.68	-3.91
Interest & Investment Income	-	15.3	14.36	16.86	7.43	0.69
Earnings From Equity Investments	-12.59	16.31	-20.06	-18.4	-17.7	12.04
Currency Exchange Gain (Loss)	78.23	78.23	-27.15	12.35	40.43	59.03
Other Non Operating Income (Expenses)	-105.57	-105.57	3.87	14.65	-15.48	-
Pretax Income	97.84	-212.65	-373.24	-474.14	-577.82	-383.94
Income Tax Expense	-643.92	15.38	4.84	7.3	5.38	-0.37
Net Income	741.76	-228.03	-378.08	-481.45	-583.19	-383.58
Net Income to Common	741.76	-228.03	-378.08	-481.45	-583.19	-383.58
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	62	61	58	56	56	55
Shares Outstanding (Diluted)	63	61	58	56	56	55
Shares Change	6.52%	4.69%	2.85%	0.38%	2.37%	8.21%
EPS (Basic)	11.96	-3.76	-6.53	-8.55	-10.40	-7.00
EPS (Diluted)	11.72	-3.76	-6.53	-8.55	-10.40	-7.00
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Free Cash Flow	335.12	45.41	-307.62	-469.8	-510.19	-441.35
Free Cash Flow Per Share	5.29	0.75	-5.31	-8.35	-9.10	-8.06
Gross Margin	91.30%	86.82%	87.83%	83.36%	76.28%	54.71%
Operating Margin	24.70%	-18.92%	-76.66%	-170.80%	-1097.85%	-5808.59%
Profit Margin	70.84%	-31.67%	-103.97%	-180.51%	-1139.63%	-4931.56%
Free Cash Flow Margin	32.01%	6.31%	-84.60%	-176.14%	-996.97%	-5674.38%
EBITDA	263.45	-131.42	-273.83	-437.11	-544.3	-436.85
EBITDA Margin	25.16%	-18.25%	-75.30%	-163.89%	-	-
D&A For EBITDA	4.79	4.86	4.94	18.43	17.51	14.95
EBIT	258.66	-136.27	-278.76	-455.54	-561.81	-451.79
EBIT Margin	24.70%	-18.92%	-76.66%	-170.80%	-	-

SEC Filings: 10-K · 10-Q